Lawsuit funding is NO LONGER AVAILABLE on Zyprexa
Of the six atypical antipsychotic medications approved by the FDA for use in the United States, Zyprexa is the most commonly prescribed. Zyprexa has been prescribed to more than 14 million people in 84 countries since 1996.
In September 2003, the FDA ordered Eli Lilly, the drug’s manufacturer, to revise Zyprexa’s label by adding a side effects warning that “hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical anti-psychotics.” Other Zyprexa side effects can include diabetes, diabetic coma, diabetic ketoacidosis, hyperglycemia, hyperosmolar coma and death.
Eli Lilly, a world leader in diabetes research, prior to marketing the drug in the US, had knowledge that the side effects of Zyprexa included diabetes, pancreatitis and severe weight gain. Nevertheless, they made the profit-driven decision to market the drug in 1996 without proper warnings to patients or doctors of these severe side effects.
The Zyprexa lawsuit is based on allegations that the Zyprexa label in use prior to March 2004 contained inadequate warnings regarding the seriousness of potential side effects.
Also, published reports indicate that as far back as the 1950’s, studies tied the use of Zyprexa and similar drugs to an increased incidence of diabetes, pancreatitis, hyperglycemia and other serious conditions. It is alleged that Eli Lilly continued to market Zyprexa without adequate warnings, despite full knowledge of this vital information.
Eli Lilly and the Zyprexa Debacle
Tens of Thousand Negligently Injured; BILLIONS In Profits Earned By Eli Lilly
In February of 2004, the American Diabetes Association, the American Psychiatric Association, the North American Association for the Study of Obesity and the American Association of Clinical Endocrinologists issued a joint statement warning the public of the association between Zyprexa and serious weight gain, diabetes and pancreatitis.
Eli Lilly and the Zyprexa Settlement
At least 8,000 people have developed serious conditions like diabetes, pancreatitis (inflammation of pancreas), ketoacidosis, hyperglycemia, seizures, diabetic coma, stroke, heart attack, amputation of a limb (due to diabetes), severe weight gain and other medical conditions.
On January 14, 2009 Eli Lilly officially settled a portion of the Zyprexa lawsuit for $1.42 billion. Putting this into some context, Eli Lilly reportedly had Zyprexa sales in excess of $37 billion since the drug was first introduced, making it one of Eli Lilly’s biggest sellers.